CStone Pharmaceuticals (HKEX: 2616), a China-based biopharmaceutical company focused on research, development, and commercialisation of innovative immuno-oncology therapies and precision medicines, announced on Tuesday that it has met the overall survival endpoint in the GEMSTONE-302 registrational clinical study of sugemalimab for the first-line treatment of metastatic (stage IV) non-small cell lung cancer (NSCLC).

The results demonstrated that sugemalimab in combination with chemotherapy indicated statistically significant and clinically meaningful overall survival improvement in patients.

The National Medical Products Administration (NMPA) of China has approved sugemalimab in combination with chemotherapy for the first-line treatment of patients with metastatic squamous and non-squamous NSCLC in December 2021, based on the earlier reported progression-free survival data. A detailed presentation of the OS analysis will be reported at an upcoming international academic conference.